O

ver the weekend, I asked my Twitter followers to weigh in on DBV Technologies’ (DBVT) chance of winning FDA approval for its experimental peanut allergy patch, given the failed phase 3 clinical trial reported Friday night.

The results, based on 900 responders:

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.